Accessibility Menu
Ani Pharmaceuticals Stock Quote

Ani Pharmaceuticals (NASDAQ: ANIP)

$95.62
(0.5%)
+0.50
Price as of October 21, 2025, 3:57 p.m. ET

KEY DATA POINTS

Current Price
$95.62
Daily Change
(0.5%) +$0.50
Day's Range
$93.66 - $95.85
Previous Close
$95.62
Open
$94.9
Beta
0.82
Volume
4,666
Average Volume
453,519
Market Cap
2.1B
Market Cap / Employee
$95.38M
52wk Range
$52.5 - $99.5
Revenue
-
Gross Margin
0.50%
Dividend Yield
N/A
EPS
-$0.77
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Ani Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ANIP+60.9%+244.08%+28.04%+1,414%
S&P+15.06%+95.03%+14.29%+323%

Ani Pharmaceuticals Company Info

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$211.37M53.1%
Gross Profit$113.48M72.9%
Gross Margin53.69%6.1%
Market Cap$1.41B5.8%
Market Cap / Employee$1.58M0.0%
Employees89739.7%
Net Income$7.73M438.0%
EBITDA$38.45M90.1%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$217.83M-9.3%
Accounts Receivable$225.65M35.9%
Inventory138.310.3%

Liabilities

Q2 2025YOY Change
Long Term Debt$633.20M104.8%
Short Term Debt$13.22M1454.8%

Ratios

Q2 2025YOY Change
Return On Assets-1.11%-3.9%
Return On Invested Capital-3.92%-0.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$71.80M453.8%
Operating Free Cash Flow$75.81M335.4%

Valuation

MetricQ4 2023Q1 2024Q2 2024YoY Change
Price to Earnings59.4940.9252.07-
Price to Book3.102.873.503.3814.22%
Price to Sales2.081.751.991.77-22.34%
Price to Tangible Book Value-5.61-5.20-7.14-7.83-233.43%
Price to Free Cash Flow TTM15.5323.2920.6510.70-14.83%
Enterprise Value to EBITDA-419.3066.0049.5945.46-28.91%
Free Cash Flow Yield6.4%4.3%4.8%9.3%17.41%
Return on Equity-2.1%-4.9%-5.2%-2.8%-149.83%
Total Debt$650.21M$655.53M$647.67M$646.41M108.46%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.